搜索
Zevra Therapeutics Inc
ZVRA添加自选
11.010USD
-0.650-5.57%
收盘 05/15, 16:00（美东）报价延迟15分钟
650.85M总市值
5.22市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-5.57%
5天
-1.08%
1月
+5.87%
6月
+23.99%
今年开始到现在
+22.88%
1年
+27.14%
TradingKey Zevra Therapeutics Inc股票评分
单位: USD 更新时间: 2026-05-15操作建议
Zevra Therapeutics Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业中等水平。增长潜力很大。当前估值合理，在药品行业排名28/155位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价23.25。中期看，股价处于上升通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Zevra Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Zevra Therapeutics Inc亮点
亮点风险
Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. It has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.
业绩高增长
公司营业收入稳步增长，连续3年增长287.71%
业绩转盈
公司业绩转盈，最新年度盈利美元
估值高估
公司最新PE估值5.22，处于3年历史高位
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值5.90K
分析师目标
根据
9
位分析师
买入
评级
23.250
目标均价
+109.08%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Zevra Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Zevra Therapeutics Inc简介
Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. It has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.
公司代码ZVRA
公司Zevra Therapeutics Inc
CEOMcfarlane (Neil F)
网址https://zevra.com/
相关品种
